Frontier Biotechnologies (SHSE:688221) Accounts Payable: ¥30.8 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688221 Frontier Biotechnologies Inc SHSE:688221
67 GF Score
Price ¥21.22
GF Value ¥37.54
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Frontier Biotechnologies Accounts Payable?

Frontier Biotechnologies SHSE:688221 +11.27% 67 Accounts Payable is ¥30.8 Mil as of Mar. 2026. GuruFocus rates SHSE:688221 with a GF Score™ of 67/100 and a GF Value™ of ¥37.54 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Frontier Biotechnologies's Accounts Payable for the quarter that ended in Mar. 2026 was ¥30.8 Mil.

Frontier Biotechnologies's quarterly Accounts Payable increased from Sep. 2025 (¥29.8 Mil) to Dec. 2025 (¥47.1 Mil) but then declined from Dec. 2025 (¥47.1 Mil) to Mar. 2026 (¥30.8 Mil).

Frontier Biotechnologies's annual Accounts Payable declined from Dec. 2023 (¥17.4 Mil) to Dec. 2024 (¥6.8 Mil) but then increased from Dec. 2024 (¥6.8 Mil) to Dec. 2025 (¥47.1 Mil).

Frontier Biotechnologies Accounts Payable Related Terms

Frontier Biotechnologies Accounts Payable Historical Data

* Premium members only.

The historical data trend for Frontier Biotechnologies's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frontier Biotechnologies Accounts Payable Chart

Frontier Biotechnologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.08 24.99 17.44 6.78 47.06

Frontier Biotechnologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.03 43.43 29.84 47.06 30.81
SHSE:688221
67GF Score
Frontier Biotechnologies Inc SHSE:688221
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Frontier Biotechnologies Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of ¥30.8 Mil mean?
Frontier Biotechnologies (SHSE:688221) has a Accounts Payable of ¥30.8 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Frontier Biotechnologies and its competitors.
Is Frontier Biotechnologies' Accounts Payable too high?
Frontier Biotechnologies' current Accounts Payable is ¥30.8 Mil. Overall, Frontier Biotechnologies has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Frontier Biotechnologies' Accounts Payable compare to ZTS?
Frontier Biotechnologies' Accounts Payable of ¥30.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Frontier Biotechnologies and its competitors. Frontier Biotechnologies's current Accounts Payable is ¥30.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Frontier Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Frontier Biotechnologies (SHSE:688221) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥37.54, compared to a current price of ¥21.22 — trading 43.5% below its estimated fair value. The current Accounts Payable is ¥30.8 Mil. Frontier Biotechnologies' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Frontier Biotechnologies (SHSE:688221), the current Accounts Payable is ¥30.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Frontier Biotechnologies (SHSE:688221) Overvalued in 2026?

Based on GuruFocus' analysis, Frontier Biotechnologies stock appears to be undervalued. The current stock price of ¥21.22 is trading 43.5% below its estimated GF Value™ of ¥37.54. GuruFocus considers Frontier Biotechnologies to be Significantly Undervalued.

Key valuation signals for SHSE:688221:

  • Accounts Payable: ¥30.8 Mil
  • GF Value™: ¥37.54 vs. price of ¥21.22 (43.5% below fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the SHSE:688221 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Frontier Biotechnologies Business Description

Address Dongshan Street, 11th Floor, Building E-2, Greenland Window, Jiangning District, Jiangsu Province, Nanjing, CHN, 211199
Frontier Biotechnologies Inc is engaged in the Research, development, production, and marketing of inventive drugs that address unmet clinical needs.
67GF Score

Get the complete analysis for SHSE:688221

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥21.22
Price
¥37.54
GF Value